Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects
Status:
Completed
Trial end date:
2017-07-20
Target enrollment:
Participant gender:
Summary
The study will evaluate the within-subject variability of 20mg ER torsemide as compared to
20mg IR torsemide (Demadex) in fully replicate double-crossover trial in healthy volunteers,
who are consuming a high-salt diet (300 mmol/day). The study will also evaluate the effects
of ER torsemide and IR torsemide on 24h sodium excretion and total urinary excretion.